| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911443 | Lung Cancer | 2011 | 5 Pages |
Abstract
Cisplatin and irinotecan combination chemotherapy appears to be acceptable for advanced thymic carcinoma as first-line chemotherapy with respect to efficacy, toxicity, and usage in the clinical setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yusuke Okuma, Yukio Hosomi, Yusuke Takagi, Mari Iguchi, Tatsuru Okamura, Masahiko Shibuya,